Decongestant

Kenvue Inc.: Please contact the Portnoy Law Firm to recover your losses; December 8, 2023 deadline.

Retrieved on: 
Tuesday, November 7, 2023

​LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) investors that a lawsuit filed on behalf of investors that purchased Kenvue securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s May 2023 initial public offering (the “IPO” or “Offering”).

Key Points: 
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 844-767-8529 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • However, shortly after the IPO, an FDA panel unanimously declared that oral forms of PE were ineffective in relieving nasal congestion.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

Kenvue Inc.: Please contact the Portnoy Law Firm to recover your losses; December 8, 2023 deadline

Retrieved on: 
Saturday, October 14, 2023

LOS ANGELES, Oct. 13, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) investors that a lawsuit filed on behalf of investors that purchased Kenvue securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s May 2023 initial public offering (the “IPO” or “Offering”).

Key Points: 
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 844-767-8529 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • However, shortly after the IPO, an FDA panel unanimously declared that oral forms of PE were ineffective in relieving nasal congestion.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

Aptar Reports First Quarter 2023 Results

Retrieved on: 
Thursday, April 27, 2023

Beauty dispensing solutions, especially in prestige fragrance, as well as mass fragrance, color cosmetics and sun care drove the positive results in the quarter.

Key Points: 
  • Beauty dispensing solutions, especially in prestige fragrance, as well as mass fragrance, color cosmetics and sun care drove the positive results in the quarter.
  • Core sales for the Aptar Closures segment declined compared with the prior year’s quarter due primarily to pass-throughs of lower raw material costs.
  • Aptar reported first quarter earnings per share of $0.82, a decrease of 12%, compared to $0.93 reported a year ago.
  • There will be a conference call held on Friday, April 28, 2023 at 8:00 a.m. Central Time to discuss the Company’s first quarter results for 2023.

Watch out for dangerous combinations of over-the-counter cold medicine and prescription drugs – two pharmacoepidemiology experts explain the risks

Retrieved on: 
Friday, April 21, 2023

When colds, flus and allergies hit, many people automatically turn to over-the-counter medications to push through and treat their symptoms.

Key Points: 
  • When colds, flus and allergies hit, many people automatically turn to over-the-counter medications to push through and treat their symptoms.
  • Nearly 70% of adults in the U.S. use over-the-counter medications as a first-line response for treating cold and flu symptoms.
  • We are a pharmacoepidemiologist and pharmacist team and we investigate adherence to medications and potential harms of medications associated with drug-drug interactions.
  • Another study estimated that every year, 26,735 people went to the emergency room for adverse events related to over-the-counter cold and cough medications.

The dangers of mixing medications

    • Pharmacists and physicians are typically knowledgeable about potential drug interactions, so it is very important for patients to ask their health care providers which over-the-counter medications are safe for them to use.
    • It is important to read the package ingredients of over-the-counter medications closely to avoid duplication of doses.
    • Cold medications are typically made up of multiple ingredients, including pain relievers, nasal decongestants and cough suppressants or expectorants.
    • Combining these decongestants with monoaminooxidase inhibitors or tricyclic antidepressants could lead to very high blood pressure and heart rhythm problems.

Each person responds to drugs differently

    • As we age, our bodies begin to lose the ability to efficiently clear drugs, which increases the risk of adverse events and unintentional overdoses.
    • Some drugs can be dangerous for people who have particular health conditions.
    • In addition, since these drugs are associated with increased blood pressure, patients with hypertension, hyperthyroidism or heart disease should be careful when using them, or avoid them altogether.

Alternatives for children

    • The Food and Drug Administration and the Centers for Disease Control and Prevention do not recommend giving cold medications to children under age 4.
    • Because of a variety of factors, young children have a higher risk of accidental overdose and adverse events that could lead to death.
    • Research has shown that honey can be helpful for reducing cold and flu symptoms in children older than age 1.

Pregnancy best practices

    • Acetaminophen is the doctor-recommended over-the-counter medication for management of pain and fever at any stage of pregnancy.
    • Any other pain relievers or anti-inflammatory medicine such as ibuprofen, ketoprofen, naproxen and aspirin should not be taken during pregnancy without a doctor’s approval.
    • For symptoms such as nasal congestion during pregnancy, a decongestant called oxymetazoline in its intranasal form is the drug of choice.

Xlear Files Amended Answer to the Government’s Lawsuit on COVID-19 Statements; Provides Still More Data In Support of Xlear’s Use as Additional Layer of Protection

Retrieved on: 
Monday, August 15, 2022

Nate Jones, CEO of Xlear noted, The Government agrees, Xlear is a saline nasal solution.

Key Points: 
  • Nate Jones, CEO of Xlear noted, The Government agrees, Xlear is a saline nasal solution.
  • New in silico research determined that compounds of grapefruit seed extract (GSE) were effective inhibitors of the SARS-CoV-2 virus.
  • Most importantly, these experts concluded natural GSEwhich is a component of Xlearwas more effective than synthetic versions of the compound.
  • As part of its efforts to silence Xlear, the Government asked the Utah Federal Court to preclude Xlear from filing the Amended Answer.

Two Day Online Course: FDA's Regulation of OTC Drug Products - What It Is, How to Analyze It, Make It Work for You (August 10-11, 2021) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 26, 2021

The "FDA's Regulation of OTC Drug Products - What It Is, How to Analyze It, Make It Work for You" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "FDA's Regulation of OTC Drug Products - What It Is, How to Analyze It, Make It Work for You" conference has been added to ResearchAndMarkets.com's offering.
  • Available without a prescription and for purchase directly off-the-shelf, OTC drug products currently represent nearly 60% of all drug products sold in the United States.
  • Some of the most recognized OTC drug products include ibuprofen tablets, anti-itch creams, nasal decongestant sprays, cough syrups, antacids, allergy medicines and topical pain relievers.
  • The U.S. Food and Drug Administration ("FDA") is responsible for the regulation and oversight of the U.S. OTC drug market.

Global Sinusitis Drugs Market Value to Increase by $ 466.44 Million During 2021-2025 | 39% Growth to Originate from North America | Technavio

Retrieved on: 
Monday, March 8, 2021

NEW YORK, March 8, 2021 /PRNewswire/ -- The global sinusitis drugs market is set to grow by USD 466.44 million during 2020-2024.

Key Points: 
  • NEW YORK, March 8, 2021 /PRNewswire/ -- The global sinusitis drugs market is set to grow by USD 466.44 million during 2020-2024.
  • Technavio segments the Sinusitis drugs market by product (steroid nasal sprays, antibiotics, decongestants, and other drugs) and geography (North America, Europe, Asia, and ROW).
  • The report identifies the rising prevalence of sinusitis as one of the major factors propelling the market growth.
  • All these factors are contributing to the growth of the global sinusitis drugs market.

Inhalation & Nasal Sprays Generic Drugs Market Research Report by Indication, by Age Group, by Class, by Route, by Distrubution Channel - Global Forecast to 2025 - Cumulative Impact of COVID-19

Retrieved on: 
Thursday, July 30, 2020

Based on Class, the Inhalation & Nasal Sprays Generic Drugs Market studied across Allergy Blocker, Anticholinergic, Antihistamine, Decongestant, Mast Cell Inhibitor, and Nasal Steroid.

Key Points: 
  • Based on Class, the Inhalation & Nasal Sprays Generic Drugs Market studied across Allergy Blocker, Anticholinergic, Antihistamine, Decongestant, Mast Cell Inhibitor, and Nasal Steroid.
  • Based on Route, the Inhalation & Nasal Sprays Generic Drugs Market studied across Inhalation, Nasal Spray, and Tropical Lotion.
  • Based on Distrubution Channel, the Inhalation & Nasal Sprays Generic Drugs Market studied across Hospital Medical Store, Online Pharmacy, and Pharmacy Retail.
  • What are the modes and strategic moves considered suitable for entering the Global Inhalation & Nasal Sprays Generic Drugs Market?

Global Sinusitis Drugs Market 2019-2023| 6% CAGR Projection Over the Next Five Years | Technavio

Retrieved on: 
Tuesday, June 11, 2019

The global sinusitis drugs market is expected to post a CAGR of over 6% during the period 2019-2023, according to the latest market research report by Technavio .

Key Points: 
  • The global sinusitis drugs market is expected to post a CAGR of over 6% during the period 2019-2023, according to the latest market research report by Technavio .
  • View the full release here: https://www.businesswire.com/news/home/20190611005620/en/
    Technavio has published a new market research report on the global sinusitis drugs market from 2019-2023 (Graphic: Business Wire)
    A key factor driving the growth of the global sinusitis drugs market is the rise in the prevalence of sinusitis.
  • This global sinusitis drugs market 2019-2023 research report also analyzes other significant trends and market drivers that will affect market growth over 2019-2023.
  • This market research report segments the global sinusitis drugs market by product (steroid nasal sprays, antibiotics, decongestants, and other drugs) and geographic regions (North America, Europe, Asia, and ROW).

New Data Highlights the Value of SPRAVATO™ (esketamine) CIII Nasal Spray, the First New Antidepressant in Decades that Works Differently for Adults with Treatment-Resistant Depression (TRD)[1]

Retrieved on: 
Tuesday, May 21, 2019

Click to Tweet: #BREAKING: New cost-efficiency data presented at #ISPOR2019 highlights the value of SPRAVATO (esketamine) CIII nasal spray for patients, payers, and society.

Key Points: 
  • Click to Tweet: #BREAKING: New cost-efficiency data presented at #ISPOR2019 highlights the value of SPRAVATO (esketamine) CIII nasal spray for patients, payers, and society.
  • Janssen also offers a comprehensive support program that helps patients get started on SPRAVATO and stay on track.
  • SPRAVATO is a prescription medicine, used along with an antidepressant taken by mouth, for treatment-resistant depression (TRD) in adults.
  • If you take a nasal corticosteroid or nasal decongestant medicine, take these medicines at least 1 hour before taking SPRAVATO.